Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - Biomarin Pharma reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $4.01 on revenue of $476.8M. Analysts polled by Investing.com EPS of $-0.11 on revenue of $454.64M.
Biomarin Pharma 's are up 37.89% and is trading at $75.09 , still down 43.09% from its 52 week high of $131.95 set on Tuesday, July 21, 2020.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on Tuesday, October 13, 2020, who reported EPS of $2.2 on revenue of $21.08B, EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on Wednesday, October 21, 2020 with third quarter EPS of $5.63 on revenue of $8.52B, for EPS of $4.33 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar